Parkinsons ≠ atrophy.
There may be atrophy, but that would be age related. Parkinsons is mostly insufficient dopamine (neurotransmitter) in the basal ganglia.
if the next drug has an effect on obesity, who is to say what it can't do yet. Time will tell.
BTW, my takeover price is >$ 80 based on trof and 1 successful future phase 2.
The next drug brand... DAYNEU.
Ann: Investor Presentation, 14 March 2023, page-90
-
- There are more pages in this discussion • 56 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.55 |
Change
0.690(3.47%) |
Mkt cap ! $2.626B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.66 | $19.94 | $5.086M | 249.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 577 | $20.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.56 | 48 | 3 |
View Market Depth
| Last trade - 15.23pm 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |